Markerless motion capture for the clinical assessment of human movement

描述（由申请人提供）：该项目的总体目标是将无标记运动捕捉系统产品化和商业化，用于生物力学和临床实践。与传统使用的基于标记的系统相反，无标记系统将为生物力学和临床实践中的应用提供简单、经济、高效和准确的人体运动3D测量。这个第二阶段项目的具体重点是使第二阶段验证的原型成为一个强大的产品，并将其商业化，用于步态分析和运动医学应用。

DESCRIPTION (provided by applicant): The overall objective of this project is to productize and commercialize a markerless motion capture system for applications in biomechanical and clinical practice. The markerless system, as opposed to traditionally used marker based systems, would provide simple, cost effective, efficient and accurate 3D measurements of human movement for applications in biomechanical and clinical practice. The specific focus of this Phase II project is to make the prototype validated in Phase II a robust product and to commercialize it for gait analysis and sport medicine applications. PUBLIC HEALTH RELEVANCE: This application proposes the development of a commercial product consisting of a markerless motion capture system that will change the way clinical assessment of human motion is achieved. The grant will enable the completion of the developments and the commercialization of this technology in research and in clinical practices. In Phase I Mixamo and Stanford University have collaborated successfully in the realization of a prototype and its validation in a clinical setup. The two institutions have the most cutting edge researchers in the human motion analysis field as members of their teams. Motion capture is one of Mixamo, Inc's. core businesses and the Stanford Biomotion Lab is where the markerless technology was born. The founding CEO of Mixamo, Stefano Corazza, has been working on the early stagees of the technology at the Stanford Biomotion Lab and he is P.I. of the present grant. In this Phase II application Mixamo is taking the lead in making a product ready for the market and commercializing it. The technology has come a long way and is ready for a revolutionary impact in the market of clinical gait analysis and biomechanics.